Trial Profile
A phase I trial of topical ETX 1153a
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 24 Oct 2012
Price :
$35
*
At a glance
- Drugs ETX 1153 (Primary)
- Indications Methicillin-resistant Staphylococcus aureus infections
- Focus Adverse reactions
- 22 Oct 2012 Status changed from planning to discontinued, according to an e-Therapeutics media release.
- 28 Jul 2011 New trial record